Should You Buy Profound Medical Corp. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Profound Medical Corp. (PROF) carries a solid Quality of Company rating of 6.8/10. Trading at $5.68, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 1 of 2 CirclFi valuation models project upside for Profound Medical Corp. (PROF) at $5.68 — the models are evenly split, with a Quality Score of 6.8/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Profound Medical Corp. (PROF) in 2026?
What Is the Bull Case vs the Bear Case for Profound Medical Corp. (PROF)?
| Bull case — $6.13 target (+7.9%) | Bear case — $0.36 target (-93.7%) |
|---|---|
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Profound Medical Corp.'s revenue and margin trajectory in the Medical Devices space. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.36 (-93.7%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +101.6% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. | |
| Industry headwind: generic/biosimilar competition represents a meaningful risk for Profound Medical Corp. and its Medical Devices peers. |
How Does PROF Compare to Its Medical Devices Peers?
Valuation data pages: SENS · HYPR · NEOG · GKOS · ATEC · RCEL · QDEL · HSCS · INMD · IRMD · PODD
Which Other Stocks Score Like PROF on Quality?
Closest companies to PROF’s Quality of Company score of 6.8/10, across all industries.
- SLSN — Solesence, Inc. (QOC 6.8) · analysis
- NIU — Niu Technologies (QOC 6.8) · analysis
- ANIK — Anika Therapeutics, Inc. (QOC 6.8) · analysis
- OR — OR Royalties Inc. (QOC 6.8) · analysis
- YSG — Yatsen Holding Limited (QOC 6.8) · analysis
- BLX — Bladex Inc. (QOC 6.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does PROF Appear In?
So Is Profound Medical Corp. (PROF) Worth Buying in 2026?
Our models don't have a clear verdict on Profound Medical Corp.. At $5.68 vs. $3.24 median fair value, the median upside of -42.9% masks significant model disagreement (+101.6% spread). With quality at 6.8/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Profound Medical Corp.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PROF Stock?
Should I buy PROF stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for PROF at $5.68. The models are divided, which means the investment case depends heavily on your assumptions about Profound Medical Corp.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Profound Medical Corp.?
Key risks include: limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (1616% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does PROF compare to its competitors?
Among Medical Devices peers, PROF holds a Quality Score of 6.8/10. Comparable companies include SENS (QOC 6.8), HYPR (QOC 6.8), NEOG (QOC 6.9). The relative ranking helps investors identify whether PROF offers better fundamental quality than alternatives in the same sector.
Is PROF a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PROF's Quality Score of 6.8/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy PROF at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $0.36 to $6.13. At $5.68, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PROF.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad